TAKEDA-PHARMACEUTICAL
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK ) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland.
“Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.”
Corporate Knights highlighted Takeda’s performance in the following areas:
- Significant year-on-year improvement in energy, water and greenhouse gas productivity scores.
- High marks for clean revenue, which measures revenue earned by providing access to medicine for top priority diseases in low- and middle-income countries through equitable pricing strategies.
- Three times the average score for female representation among senior executives.
In addition to the Global 100 index, Takeda is recognized by many other environmental, social and governance (ESG) investment valuations. As a long-standing member of the United Nations Global Compact, Takeda’s sustainability efforts are guided by key international targets, such as the Sustainable Development Goals (SDGs).
Name of
|
Company/
|
Country |
History of
|
Dow Jones Sustainability World Index |
Dow Jones |
U.S. |
1st year |
Dow Jones Sustainability Asia Pacific Index |
Dow Jones |
U.S. |
10th year |
FTSE4Good Developed Index |
FTSE Russell |
U.K. |
15th consecutive year |
MSCI ESG Leaders Index |
MSCI |
U.S. |
10th consecutive year |
Ethibel EXCELLENCE Investment Register |
Forum Ethibel |
BEL |
Since July 2017 |
Prime Status |
ISS-Oekom |
GER |
2nd consecutive year |
Industry Mover Sustainability Yearbook Award 2019 |
RobecoSAM |
CHE |
Since February 2019 |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK
) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit www.takeda.com
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005554/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine kompetencer inden for digital transformation med Criticalcase14.11.2025 19:44:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med Criticalcase, der er et europæisk firma med speciale i cloud-infrastruktur, cybersikkerhed og administrerede it-tjenester. Criticalcase blev grundlagt i 1999 og har hovedsæde i Italien og har markeret sig inden for cloud-sektoren ved at designe og vedligeholde komplekse infrastrukturer for mellemstore og store virksomheder. Gennem skræddersyede løsninger tilbyder virksomheden et omfattende udvalg af tjenester, herunder sikkerhed, overvågning døgnet rundt og systemadministration, hvilket skaber pålidelighed, optimal ydeevne og beskyttelse helt ned til operativsystemniveau. "Vores mission har altid været at guide kunder gennem komplekse teknologiske udfordringer med en strategisk og praktisk tilgang," siger Luca Nunno, der er CEO for Criticalcase. "Samarbejdet med Andersen Consulting giver os mulighed for at få vores ekspertise ud til et bredere globalt publikum og skabe værdi gennem innovation og digital ekspert
Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 11:15:00 CET | Press release
AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on Novem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
